Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03126591
Title A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company



Olaratumab + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | FRA | BEL

No variant requirements are available.